EACH ISSUE CONTAINS

Conferences
Important information on the discovery and development of drugs is often disclosed at scientific conferences long before publication in the primary literature. IDrugs provides unparalleled coverage of scientific conferences through its network of scientific reporters, who attend meetings in their fields of expertise, and are thus able to provide expert opinions on the presentations and data disclosed. Thomson Reuters commissions reports from over 300 scientific conferences each year, and the best of these are published in IDrugs, within weeks of the event.

Features
Feature reviews provide expert viewpoints on hot topics from within the pharmaceutical, technology, regulatory and financial industries, as well as academia. Features offer a forum for discussion of important issues or controversy in the drug R&D community. The articles are presented in an informative and thought-provoking style, and are written with qualified but non-specialist researchers in mind.

Drug profiles
Expert commentary on the scientific and commercial potential of selected drugs in clinical trials in the form of drug profiles. A drug profile is a review of the available literature (scientific and commercial) and acts as an expert guide to the bibliography, highlighting references of particular interest. Opinion on the drug’s potential, with a personal viewpoint on its therapeutic and economic viability, are included. Further information on these drugs appears in Thomson Reuters' Investigational Drugs database (IDdb) and Thomson Pharma platform.

Deal Highlights/Deals Landscape
Deal Highlights keep readers informed of the monthly deal activities occurring within the bio/pharmaceutical industry, ranging from technology acquisitions and R&D collaborations to the acquisitions of territorial and marketing rights. Particularly notable deals are highlighted in Deals Landscape articles, published on a quarterly basis.